Highflyer 2007 wetten...
| eröffnet am: | 01.01.07 05:16 von: | Superflach |
| neuester Beitrag: | 13.07.18 23:35 von: | cultom4president |
| Anzahl Beiträge: | 77 | |
| Leser gesamt: | 22984 | |
| davon Heute: | 3 | |
bewertet mit 5 Sternen |
||
|
Seite:
1
|
2
|
||
06.01.10 22:01
#26
el bundy
sk 6.79$
morgen kann es erst über 6.90 gap geben
sieht weiterhin fein aus
sieht weiterhin fein aus
07.01.10 14:04
#28
el bundy
mal sehen wenn es vorbörslich los geht
http://www.nasdaq.com/aspx/...ol=ABC&symbol=AKF&selected=SIGA
19.01.10 18:52
#36
cultom4president
@ ElBundy
Bist du nur ein Schönwetter-Poster? ;o)
Siga hatte in den letzten Tagen einiges wieder abgegeben, heute mal wieder schönes Volumen auf der Käuferseite.
Wann rechnet man mit positiven News in Bezug auf St-246, bin gerade dabei mich in diesem Wert einzulesen.
cultom
Siga hatte in den letzten Tagen einiges wieder abgegeben, heute mal wieder schönes Volumen auf der Käuferseite.
Wann rechnet man mit positiven News in Bezug auf St-246, bin gerade dabei mich in diesem Wert einzulesen.
cultom
19.01.10 19:01
#37
cultom4president
Ach, es gab eine NEWS heute!
SRAEL TAPS SIGA TECHNOLOGIES' ST-246® TO COMBAT SMALLPOX IN SIMULATED BIOTERROR ATTACK
NEW YORK, January 19, 2010 - SIGA Technologies, Inc. (Nasdaq: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it was contacted to arrange an emergency mock acquisition of its lead drug candidate and smallpox antiviral, ST-246® (Tecovirimat), by leading Israeli government health and defense officials. The mock acquisition was part of a simulated bioterror-related smallpox outbreak.
Dubbed Orange Flame 4, the simulation was the largest biodefense drill in Israeli history, and it capped a four-day conference recognized by the World Health Organization and co-sponsored the Home Front Command of the Israeli Defense Forces.
"While no drug was actually delivered in this exercise, Israeli authorities told us they had arranged for immediate transportation of as many courses as we could provide, fully understanding that our drug candidate is under advanced development with BARDA and not registered with FDA," said Eric A. Rose, MD, SIGA's Chief Executive Officer.
Dr. Rose was among the hundreds of experts from over 70 countries that observed the two-day exercise that took place in and around Tel Aviv, Israel.
As part of the scenario, two European nationals, who were supposedly infected with smallpox, posed as tourists and "exposed" the public at a number of high-traffic locations, including a hotel and sports stadium. The simulation involved more than 20,000 smallpox-exposed individuals who required immediate isolation and treatment, as well as initiation of a nationwide vaccination campaign.
"Israel is committed to, and an internationally recognized thought leader in, safety and preparedness. This exercise was an excellent opportunity to observe a full simulation of a biological attack. It highlighted that a bioterror attack is a highly plausible scenario, which poses a significant threat to all civilized society. Observers of this exercise understood that the two critical elements in minimizing the after-effects of a bioterror attack are efficient planning and safe and effective medical countermeasures," concluded Dr. Rose.
ST-246 has been used in three compassionate use cases in the United States and will be undergoing final safety and toxicity trials as part of the U.S. regulatory approval process. The company also has bid for a contract under an outstanding request for proposal by BARDA to supply the Strategic National Stockpile with a smallpox antiviral.
www.siga.com/?ID=131
NEW YORK, January 19, 2010 - SIGA Technologies, Inc. (Nasdaq: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it was contacted to arrange an emergency mock acquisition of its lead drug candidate and smallpox antiviral, ST-246® (Tecovirimat), by leading Israeli government health and defense officials. The mock acquisition was part of a simulated bioterror-related smallpox outbreak.
Dubbed Orange Flame 4, the simulation was the largest biodefense drill in Israeli history, and it capped a four-day conference recognized by the World Health Organization and co-sponsored the Home Front Command of the Israeli Defense Forces.
"While no drug was actually delivered in this exercise, Israeli authorities told us they had arranged for immediate transportation of as many courses as we could provide, fully understanding that our drug candidate is under advanced development with BARDA and not registered with FDA," said Eric A. Rose, MD, SIGA's Chief Executive Officer.
Dr. Rose was among the hundreds of experts from over 70 countries that observed the two-day exercise that took place in and around Tel Aviv, Israel.
As part of the scenario, two European nationals, who were supposedly infected with smallpox, posed as tourists and "exposed" the public at a number of high-traffic locations, including a hotel and sports stadium. The simulation involved more than 20,000 smallpox-exposed individuals who required immediate isolation and treatment, as well as initiation of a nationwide vaccination campaign.
"Israel is committed to, and an internationally recognized thought leader in, safety and preparedness. This exercise was an excellent opportunity to observe a full simulation of a biological attack. It highlighted that a bioterror attack is a highly plausible scenario, which poses a significant threat to all civilized society. Observers of this exercise understood that the two critical elements in minimizing the after-effects of a bioterror attack are efficient planning and safe and effective medical countermeasures," concluded Dr. Rose.
ST-246 has been used in three compassionate use cases in the United States and will be undergoing final safety and toxicity trials as part of the U.S. regulatory approval process. The company also has bid for a contract under an outstanding request for proposal by BARDA to supply the Strategic National Stockpile with a smallpox antiviral.
www.siga.com/?ID=131
19.01.10 22:03
#39
el bundy
c4p
jetzt ging es aber am ende nochmal einen hüpfer hoch
bei siga und palm
bei siga und palm
28.01.10 14:34
#41
el bundy
hehehehe
wollt ich gerad auch psoten
wir sind hier alleine,bei solch einem wert
mir völlig unverständlich
wir sind hier alleine,bei solch einem wert
mir völlig unverständlich
28.01.10 14:41
#42
el bundy
es gibt bisher nix zu finden
aber tritzdem haben wir vorbörslich nicht wenig volumen
28.01.10 14:44
#43
cultom4president
*
Dies wundert mich nicht wirklich bei solch einem kleinen Biotechunternehmen. Hier gibt es keine "Aktionär" der SIGA ins Depot aufnimmt, da ist eigenen Recherche gefragt. :o)
Mal schauen was heute passiert - entweder da ist was durchgesickert und die NEWS kommt die Tage oder eben einfach nur mal ein Ausreisser, ging ja auch tagelang bergab.
Mal schauen was heute passiert - entweder da ist was durchgesickert und die NEWS kommt die Tage oder eben einfach nur mal ein Ausreisser, ging ja auch tagelang bergab.
28.01.10 14:51
#45
achilles77
----
schön, dass es hier bergaauf geht. denke in zukunft wird da noch was kommen. wollen wir mal geduldig bleiben :-)
28.01.10 14:54
#46
el bundy
na
wenigstens ein mohikaner
du weisst bescheid,nächstes essen in der hauptstadt
du weisst bescheid,nächstes essen in der hauptstadt
28.01.10 14:55
#47
cultom4president
Des Rätsels Lösung ...
.... Coverage von RBS
http://www.streetinsider.com/New+Coverage/...RBC+Capital/5282984.html
Kursziel 11USD!
Na ist doch mal was!
http://www.streetinsider.com/New+Coverage/...RBC+Capital/5282984.html
Kursziel 11USD!
Na ist doch mal was!
Seite:
1
|
1
|
2